Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:42
  • Home
  • Print this page
  • Email this page

 Table of Contents  
Year : 2016  |  Volume : 1  |  Issue : 1  |  Page : 20

Platelet crossmatching

From the Chairperson and Head, Department of Blood Transfusion Medicine, Sir Ganga Ram Hospital, New Delhi, India

Date of Web Publication3-Mar-2016

Correspondence Address:
Vivek Ranjan
From the Chairperson and Head, Department of Blood Transfusion Medicine, Sir Ganga Ram Hospital, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2455-8893.177998

Rights and Permissions

How to cite this article:
Ranjan V. Platelet crossmatching. Glob J Transfus Med 2016;1:20

How to cite this URL:
Ranjan V. Platelet crossmatching. Glob J Transfus Med [serial online] 2016 [cited 2022 Oct 1];1:20. Available from: https://www.gjtmonline.com/text.asp?2016/1/1/20/177998

In current practice, platelet transfusion begins with randomly selected platelets, either whole blood derived platelet concentrates or platelet prepared by apheresis. This approach continues until the patient is refractory. Most immunogenic refractoriness results from antibodies to human leukocyte antigen (HLA). It is important to emphasize that clinical refractoriness is often due not to alloimmunization but, rather, to clinical factors such as infection, splenomegaly, or disseminated intravascular coagulation. This, it would make sense to perform one or more serologic tests to prove that alloimmunization was present before taking any decision to platelet transfusion. In such condition, HLA-matched platelet (once HLA phenotype in known); crossmatched platelets or HLA antigen negative platelet are the choices for better response and controlled hemostasis. In general, platelets are required immediately or very soon and the method employed is based upon the availability. Crossmatched platelet may be obtained more quickly than HLA-matched platelets. In addition crossmatched platelets can be used both for diagnosis and treatment, as antibody detection is inherent to its testing process. Crossmatched products have been shown to have a longer survival post-transfusion than un-crossmatched platelets. Another benefit of cross-matching as compared to HLA-matched platelet is the potential larger pool of compatible donor.

With the advancement of technology for the management of platelet alloimmunization, crossmatching is an excellent way to begin support in a patient needing product urgently. It provides a quick answer to the question of whether or not the patient is alloimmunized.[1]

  References Top

Mangwana S, Simon N. Evaluation of the platelet cross-matching in oncology patients. Glob J Transfus Med 2016;1:16-9.  Back to cited text no. 1
  Medknow Journal  


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded124    
    Comments [Add]    

Recommend this journal